Canadian Medical Cannabis Review Adds New Voice to Call for Better Research
Original story from University of Alberta Faculty of Medicine & Dentistry
A new medical guideline suggests Canada’s family physicians should take a sober second thought before prescribing medical cannabis to most patients.
Published in Canadian Family Physician, “Simplified Guideline for Prescribing Medical Cannabinoids in Primary Care” states there is limited evidence to support the reputed benefits of medical marijuana for many conditions, and what benefits do exist may be balanced out or even outweighed by the harms.
“While enthusiasm for medical marijuana is very strong among some people, good-quality research has not caught up,” said Mike Allan, director of evidence-based medicine at the University of Alberta and project lead for the guideline.
The guideline was created after an in-depth review of clinical trials involving medical cannabis and will be distributed to roughly 30,000 clinicians across Canada. It was overseen by a committee of 10 individuals, supported by 10 other contributors, and peer-reviewed by 40 others, each a mixture of doctors, pharmacists, nurse practitioners, nurses and patients. The review examined cannabinoids for the treatment of pain, spasticity, nausea, and vomiting, as well as their side-effects and harms.
Researchers found that in most cases the number of randomized studies involving medical cannabis is extremely limited or entirely absent. The size and duration of the studies that do exist are also very narrow in scope.
“In general we’re talking about one study, and often very poorly done,” said Allan. “For example, there are no studies for the treatment of depression. For anxiety, there is one study of 24 patients with social anxiety in which half received a single dose of cannabis derivative and scored their anxiety doing a simulated presentation. This is hardly adequate to determine if lifelong treatment of conditions like general anxiety disorders is reasonable.”
Limited evidence of benefits
According to the guideline, there is acceptable research for the use of medical cannabinoids to treat a handful of very specific medical conditions. They include chronic neuropathic (nerve) pain, palliative cancer pain, spasticity associated with multiple sclerosis or spinal cord injury, and nausea and vomiting from chemotherapy. Even in those specific cases, the benefits were found to be generally minor.
For nerve pain, 30 percent of patients given a placebo saw a moderate improvement in their pain while 39 percent experienced the same effect while on medical cannabinoids. In patients with muscle spasticity, 25 percent of those taking a placebo saw a moderate improvement compared to 35 percent on medical cannabis. The use of medical cannabis was best supported in its use for chemotherapy patients experiencing nausea and vomiting. Just under half of patients using cannabinoids for their symptoms had an absence of nausea and vomiting compared to 13 percent on placebo.
“Medical cannabinoids should normally only be considered in the small handful of conditions with adequate evidence and only after a patient has tried a number of standard therapies,” said Allan. “Given the inconsistent nature of medical marijuana dosing and possible risks of smoking, we also recommend that pharmaceutical cannabinoids be tried first before smoked medical marijuana.”
While the researchers found evidence supporting the use of medical cannabinoids to be limited, side-effects were both common and consistent. About 11 percent of patients were not able to tolerate medical cannabinoids, versus three percent of those taking a placebo. Common effects included sedation (50 percent versus 30 percent), dizziness (32 percent versus 11 percent) and confusion (nine percent versus two percent).
“This guideline may be unsatisfactory for some, particularly those with polarized views regarding medical cannabinoids,” said Allan.
He added that those who oppose the use of cannabinoids for medical therapy may be disappointed that the guideline considers medical cannabinoids in specific cases. Others, who feel cannabinoids are highly effective and don’t pose any risk, may be frustrated that the guideline doesn’t advocate their use sooner or for a broader range of conditions.
“Better research is definitely needed—randomized control trials that follow a large number of patients for longer periods of time. If we had that, it could change how we approach this issue and help guide our recommendations.”